Jubilant Pharmova posts robust Q3, eyes Vision 2030 with sterile injectables drive
The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses
The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
The PRIOH-1 study met its primary endpoint, delivering statistically significant and clinically meaningful improvements in lesion healing
These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke
HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors
The approved scheme will deliver around 1 million sq ft of state-of-the-art laboratory and research space across a 12-acre site
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
Topiramate Extended-Release Capsules are bioequivalent to the reference listed drug (RLD), Trokendi XR Extended-Release Capsules of Supernus Pharmaceuticals
Operating profit fell 1% in Danish kroner to DKK 127.7 billion but rose 6% at constant exchange rates
Subscribe To Our Newsletter & Stay Updated